Canine genetic company Embark Veterinary raises $75M
The company aims to increase the lifespan of dogs by three years within the next decade.
Embark will use the new funding to expand on key hires and accelerate the development of its robust discovery engine. As Embark’s database expands, the company will be able to exponentially increase the number of novel discoveries it makes to help dogs live healthier, longer lives.
“If there’s one thing we’ve learned over the past year, it’s that there’s nothing more important than the health of our family — and pets are a big part of our families,” said Ryan Boyko, Co-Founder and CEO of Embark. “We’re proud to be partnering with veterinarians, breeders, and dog owners all around the world to substantially increase the life and healthspan for all dogs, and — ultimately — for humans as well.”
Embark’s Dog DNA Test tests for over 350 breeds, more than 200 genetic health risks, and many physical traits to empower dog owners, breeders, and veterinarians to make personalized care plans based on their dog’s unique genetic profile. Embark’s proprietary genotyping technology analyzes 200,000 genetic markers. With all this data, the company is in a good position to make novel discoveries about health risks, traits, and breeds.
The round was led by Lydia Jett of SoftBank Vision Fund 2.